Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02999854 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
A Phase 3 study, sponsored by Kiadis Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT02999854: Clinical Trial Phase 3 study, sponsored by Kiadis Pharma.
NCT02999854 is a Phase 3 study that was terminated before completion, run by Kiadis Pharma. The registered enrollment target is 63 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02999854, a Phase 3 study, was terminated before completion, sponsored by Kiadis Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic malignancy. An additional objective of the study is to compare the effect of the two treatments on quality of life.
Primary Outcome
Defined as the time until acute GVHD grade III/IV, chronic GVHD requiring systemic treatment, relapse, or death, whichever occurs first. Kaplan-Meier estimates (percentage of participants) of GRFS were calculated at 24 months post HSCT.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL ATIR101
- PROCEDURE T-cell depleted HSCT from a related, haploidentical donor
- PROCEDURE T-cell replete HSCT from a related, haploidentical donor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2021-12-17 |
| Phase | Phase 3 |
Why NCT02999854 stopped before completion
NCT02999854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02999854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02999854 about?
NCT02999854 is a clinical study titled "Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer". The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic mal...
What is the current status of trial NCT02999854?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2017-11-29. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT02999854?
The interventions under investigation include: Cyclophosphamide (DRUG), ATIR101 (BIOLOGICAL), T-cell depleted HSCT from a related, haploidentical donor (PROCEDURE), T-cell replete HSCT from a related, haploidentical donor (PROCEDURE).
Who is sponsoring clinical trial NCT02999854?
This trial is sponsored by Kiadis Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02999854's enrollment target sits among peer trials
63 1800th of 2000 higher than 199 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI